AP983A - Freeze-dried composition of bone morphogenetic protein human MP52. - Google Patents

Freeze-dried composition of bone morphogenetic protein human MP52. Download PDF

Info

Publication number
AP983A
AP983A APAP/P/1999/001602A AP9901602A AP983A AP 983 A AP983 A AP 983A AP 9901602 A AP9901602 A AP 9901602A AP 983 A AP983 A AP 983A
Authority
AP
ARIPO
Prior art keywords
bone morphogenetic
morphogenetic factor
factor human
mannitol
composition
Prior art date
Application number
APAP/P/1999/001602A
Other languages
English (en)
Other versions
AP9901602A0 (en
Inventor
Hideki Ichikawa
Mitsuko Inagaki
Original Assignee
Biopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopharm Gmbh filed Critical Biopharm Gmbh
Publication of AP9901602A0 publication Critical patent/AP9901602A0/xx
Application granted granted Critical
Publication of AP983A publication Critical patent/AP983A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
APAP/P/1999/001602A 1997-01-30 1998-01-29 Freeze-dried composition of bone morphogenetic protein human MP52. AP983A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1634997 1997-01-30
PCT/JP1998/000371 WO1998033514A1 (fr) 1997-01-30 1998-01-29 Composition lyophilisee de mp52 humaine de proteines morphogenetiques osseuses

Publications (2)

Publication Number Publication Date
AP9901602A0 AP9901602A0 (en) 1999-09-30
AP983A true AP983A (en) 2001-07-16

Family

ID=11913900

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1999/001602A AP983A (en) 1997-01-30 1998-01-29 Freeze-dried composition of bone morphogenetic protein human MP52.

Country Status (22)

Country Link
EP (1) EP0972520B9 (sr)
JP (1) JP4209948B2 (sr)
KR (1) KR100548107B1 (sr)
CN (1) CN1152712C (sr)
AP (1) AP983A (sr)
AT (1) ATE302021T1 (sr)
AU (1) AU737595B2 (sr)
BR (1) BR9807537B1 (sr)
CA (1) CA2278546C (sr)
DE (1) DE69831223T9 (sr)
DK (1) DK0972520T3 (sr)
EA (1) EA001579B1 (sr)
ES (1) ES2244043T3 (sr)
HU (1) HU226554B1 (sr)
IL (2) IL130967A0 (sr)
NO (1) NO322334B1 (sr)
NZ (1) NZ336509A (sr)
PL (1) PL189381B1 (sr)
RS (1) RS49691B (sr)
SI (1) SI0972520T1 (sr)
TR (1) TR199901832T2 (sr)
WO (1) WO1998033514A1 (sr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4388602B2 (ja) † 1997-02-07 2009-12-24 ストライカー コーポレイション マトリクスを含まない骨形成デバイス、移植片、およびその使用方法
WO2003030873A1 (en) * 2001-10-09 2003-04-17 Cellfactors Plc Therapeutic biological product and method for formation of new vascularised bone
CA2466947C (en) 2001-11-19 2012-05-22 Scil Technology Gmbh A homogeneously coated device having osteoinductive and osteoconductive properties
ATE322916T1 (de) 2002-09-10 2006-04-15 Scil Technology Gmbh Unter verringerter sauerstoffkonzentration mit einem osteoinduktiven protein beschichtetes metallimplantat
EP1651272A1 (en) * 2003-08-05 2006-05-03 Fuji Photo Film B.V. Use of recombinant or synthetic gelatin as a stabiliser in vaccines
CA2545458A1 (en) * 2003-11-10 2005-05-26 Arriva-Prometic Inc. Dry recombinant human alpha 1-antitrypsin formulation
JP4944010B2 (ja) 2004-03-10 2012-05-30 サイル テクノロジー ゲーエムベーハー コーティングされたインプラント、その製造および使用
US10360287B2 (en) 2015-05-22 2019-07-23 Microsoft Technology Licensing, Llc Unified messaging platform and interface for providing user callouts
US20160344677A1 (en) 2015-05-22 2016-11-24 Microsoft Technology Licensing, Llc Unified messaging platform for providing interactive semantic objects

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033215A1 (fr) * 1995-04-19 1996-10-24 Hoechst Pharmaceuticals & Chemicals K.K. Proteine nouvelle et son procede de fabrication

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3273597D1 (en) * 1981-11-28 1986-11-06 Sunstar Kk Pharmaceutical composition containing interferon in stable state
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
AU663328B2 (en) * 1991-06-21 1995-10-05 Genetics Institute, Llc Pharmaceutical formulations of osteogenic proteins
JP2966592B2 (ja) * 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
UA48105C2 (uk) * 1992-02-12 2002-08-15 Біофарм Гезельшафт Цур Біотехнологішен Ентвіклунг Вон Фармака Мбх ФРАГМЕНТ ДНК, ЯКИЙ КОДУЄ БІЛОК РОДИНИ TGF-<font face="Symbol">b</font> (ВАРІАНТИ), РЕКОМБІНАНТНА МОЛЕКУЛА ДНК (ВАРІАНТИ), КЛІТИНА-ХАЗЯЇН (ВАРІАНТИ), СПОСІБ ОДЕРЖАННЯ БІЛКУ РОДИНИ TGF-<font face="Symbol">b</font> (ВАРІАНТИ), БІЛОК РОДИНИ TGF-<font face="Symbol">b</font> (ВАРІАНТИ), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ (ВАРІАНТИ), АНТИТІЛО АБО ФРАГМЕНТ АНТИТІЛА (ВАРІАНТИ), МОЛЕКУЛА КДНК (ВАРІАНТИ)
CA2093836A1 (en) * 1992-04-24 1993-10-25 Wayne Gombotz Biodegradable tgf-.beta. delivery system for bone regeneration
DE4239877C1 (de) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
EP0814841B1 (en) * 1995-03-21 2001-12-05 Applied Research Systems ARS Holding N.V. Hcg liquid formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033215A1 (fr) * 1995-04-19 1996-10-24 Hoechst Pharmaceuticals & Chemicals K.K. Proteine nouvelle et son procede de fabrication

Also Published As

Publication number Publication date
IL130967A0 (en) 2001-01-28
SI0972520T1 (sl) 2006-02-28
DE69831223T9 (de) 2006-12-07
EA199900694A1 (ru) 2000-04-24
WO1998033514A1 (fr) 1998-08-06
HUP0002386A2 (hu) 2000-11-28
ES2244043T3 (es) 2005-12-01
CA2278546A1 (en) 1998-08-06
HUP0002386A3 (en) 2002-09-30
NO993702D0 (no) 1999-07-29
RS49691B (sr) 2007-12-31
DE69831223T2 (de) 2006-02-16
NO993702L (no) 1999-09-29
BR9807537A (pt) 2000-03-21
NZ336509A (en) 2001-03-30
KR20000070586A (ko) 2000-11-25
EP0972520B1 (en) 2005-08-17
ATE302021T1 (de) 2005-09-15
BR9807537B1 (pt) 2009-01-13
AU5679198A (en) 1998-08-25
DK0972520T3 (da) 2005-12-19
AP9901602A0 (en) 1999-09-30
KR100548107B1 (ko) 2006-02-02
DE69831223D1 (de) 2005-09-22
TR199901832T2 (xx) 1999-12-21
NO322334B1 (no) 2006-09-18
CN1244127A (zh) 2000-02-09
AU737595B2 (en) 2001-08-23
IL130967A (en) 2006-12-10
YU34999A (sh) 2002-08-12
JP4209948B2 (ja) 2009-01-14
EA001579B1 (ru) 2001-06-25
CA2278546C (en) 2008-04-01
EP0972520A4 (en) 2002-11-05
PL334852A1 (en) 2000-03-27
HU226554B1 (en) 2009-03-30
EP0972520A1 (en) 2000-01-19
CN1152712C (zh) 2004-06-09
PL189381B1 (pl) 2005-07-29
EP0972520B9 (en) 2006-03-22

Similar Documents

Publication Publication Date Title
AU627174B2 (en) Human growth hormone formulation
CA2139358C (en) Human growth hormone aqueous formulation
KR100942399B1 (ko) Ｅｇｆ 수용체에 대한 항체를 함유하는 동결건조된 제제
EP1174148A1 (en) Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same
HU202761B (en) Process for producing stabilized erythropoietin compositions
AU738413B2 (en) Human growth hormone-containing aqueous pharmaceutical composition
AP983A (en) Freeze-dried composition of bone morphogenetic protein human MP52.
US20220133633A1 (en) Pharmaceutical taci-fc fusion protein formulation
KR100377967B1 (ko) Hcg액상조성물
US5898030A (en) hGH containing pharmaceutical compositions
JPH01168624A (ja) 抗体の安定化
KR20040018458A (ko) Ｃｅｔｕｘｉｍａｂ 및 폴리옥시에틸렌 소르비탄 지방산에스테르를 포함하는 액형 제제
US20040132653A1 (en) Lyophilized composition of bone morphogenetic factor human MP52
CA1289071C (en) Pharmaceutical compositions for parenteral use containing a calcitonin as the active ingredient
MXPA99006784A (en) Freeze-dried composition of bone morphogenetic protein human mp52
RU2160605C2 (ru) Жидкие композиции, содержащие человеческий хорионический гонадотропин (hcg)
JPH01246226A (ja) 安定な修飾アスパラギナーゼ含有組成物
UA50811C2 (uk) Ліофілізована композиція морфогенетичного фактора кістки, спосіб одержання ліофілізованої композиції морфогенетичного фактора кістки
JP2005232177A (ja) Ｈｇｈ含有医薬組成物
US20160095904A1 (en) Stabilized liquid formulation
JPS62149623A (ja) 安定なｇｒｆ製剤
CA2215936A1 (en) Hcg liquid formulations